Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts’ consensus estimates.

Is now the time to buy Haemonetics? Find out by accessing our full research report, it’s free.

Company Overview

With roots dating back to 1971 and a mission to improve blood-related healthcare, Haemonetics (NYSE:HAE) provides specialized medical devices and software for blood collection, processing, and management across plasma centers, blood banks, and hospitals.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Haemonetics grew its sales at a decent 8.4% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Haemonetics’s recent performance shows its demand has slowed as its revenue was flat over the last two years.

We can dig further into the company’s sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don’t accurately reflect its fundamentals. Over the last two years, Haemonetics’s organic revenue averaged 3.2% year-on-year growth. Because this number is better than its two-year revenue growth, we can see that some mixture of divestitures and foreign exchange rates dampened its headline results.

This quarter, Haemonetics reported year-on-year revenue growth of 5.6%, and its $339.4 million of revenue exceeded Wall Street’s estimates by 2.8%.

Looking ahead, sell-side analysts expect revenue to grow 5% over the next 12 months. While this projection indicates its newer products and services will catalyze better top-line performance, it is still below average for the sector.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Adjusted Operating Margin

Haemonetics has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 21.9%.

Analyzing the trend in its profitability, Haemonetics’s adjusted operating margin rose by 5.3 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 3.4 percentage points on a two-year basis.

In Q2, Haemonetics generated an adjusted operating margin profit margin of 19.7%, down 4.5 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Haemonetics’s EPS grew at 16% compounded annual growth rate over the last five years, higher than its 8.4% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

We can take a deeper look into Haemonetics’s earnings to better understand the drivers of its performance. As we mentioned earlier, Haemonetics’s adjusted operating margin declined this quarter but expanded by 5.3 percentage points over the last five years. Its share count also shrank by 10.3%, and these factors together are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth.

In Q2, Haemonetics reported adjusted EPS of $1.14, up from $1.10 in the same quarter last year. This print beat analysts’ estimates by 5.8%. Over the next 12 months, Wall Street expects Haemonetics’s full-year EPS to grow 7% from $5.01 to $5.36.

Key Takeaways from Haemonetics’s Q2 Results

We enjoyed seeing Haemonetics beat analysts’ organic revenue expectations this quarter. We were also glad its revenue outperformed Wall Street’s estimates. Zooming out, we think this was a good print with some key areas of upside. The market seemed to be hoping for more, and the stock traded down 3.1% to $81 immediately following the results.

Is Haemonetics an attractive investment opportunity right now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).